/PAVMZ

PAVMZ Stock - PAVmed Inc

Q: What is the analyst price target for PAVMZ?

Analyst price target information is not currently available for PAVMZ.

Q: What is PAVMZ's market cap?

Market capitalization information is not currently available for PAVMZ.

Healthcare|Medical - Devices|NASDAQ

$0.00-40.00%

$0.00 (-40.00%) • Apr 30

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PAVMZ

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.14

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$3.00M	$2.45M	$377,000	$500,000	N/A
Gross Profit	$-3,043,000	$-3,968,000	$-3,237,000	$-85,000	N/A
Gross Margin	-101.6%	-161.8%	-858.6%	-17.0%	N/A
Operating Income	$-44,487,000	$-68,795,000	$-91,087,000	$-54,393,000	$-23,351,000
Net Income	$39.79M	$-64,175,000	$-88,983,000	$-50,347,000	$-34,276,000
Net Margin	1328.6%	-2617.3%	-23602.9%	-10069.4%	N/A
EPS	$3.30	$-9.16	$-15.03	$-9.80	$-10.93

Company Overview

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Visit Website